A panel at the virtual ACCC 47th Annual Meeting & Cancer Center Business Summit shared real-world experiences on the impact of the COVID-19 pandemic on cancer care delivery.
A recent study comparing brachytherapy, dose-escalated external beam radiotherapy, and stereotactic body radiation therapy for intermediate-risk localized prostate cancer, suggests that brachytherapy is the most appropriate management strategy in delivering value-based care.
KTE-X19 is a potentially cost-effective alternative to the current standard of care for relapsed/refractory MCL.
Study results show adjuvant hormonal therapy adherence at 5 years are low among commercially insured patients with breast cancer.
A methodology to identify high-value oncology care was developed using cost of care per patient per day in breast cancer episodes of initial, survivorship, and relapse care.